Michael Spinner, MD
Assistant Professor
Medicine
School of Medicine

My research focuses on novel immunotherapy approaches to treat lymphoma and personalized medicine, tailoring treatment to individual patients based on their disease characteristics and tumor genetics. I am a co-investigator on clinical trials evaluating new immunotherapies to treat lymphoma and collaborate with leading scientists on identifying biomarkers to predict which patients may benefit from certain treatments.

I received my medical degree from Vanderbilt University and completed my internal medicine residency and hematology/oncology fellowship from Stanford University under the mentorship of Dr. Ranjana Advani. I serve on the Hodgkin lymphoma guidelines committee for the National Comprehensive Cancer Network.

• Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
  Blood advances 2023 Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard …
• Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.
  Cancers 2023 Randall MP, Spinner MA
• Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy.
  European journal of nuclear medicine and molecular imaging 2023 Banerjee R, Wang V, Huang CY, Pandita D, Leonard MK, LaRue S, Ahmadi M, Kaplan L, Ai WZ, Fakhri B, Spinner M, Seshadri MR, Pampaloni MH, Andreadis CB
• Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
  Blood 2023 Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, Frank MJ, Johnston LJ, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shiraz P, Shizuru JA, Weng WK, Binkley MS, Hoppe RT, Advani RH, Arai S
• Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
  American journal of hematology 2023 Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Murphy J, Ansell S, …
• Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.
  Oncology (Williston Park, N.Y.) 2022 Spinner MA, Advani RH
• Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
  Blood 2022 Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, …
• Increased double-negative αβ+ T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease.
  Haematologica 2022 Brar N, Spinner MA, Baker MC, Advani RH, Natkunam Y, Lewis DB, Silva O
• Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
  Clinical lymphoma, myeloma & leukemia 2021 Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Malecek MK, Watkins MP, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Evens AM, Shah M, Ahmed S, Stephens DM, …
• Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant.
  Bone marrow transplantation 2021 Dworkin ML, Jiang AL, Von Eyben R, Spinner MA, Advani RH, Lowsky R, Hiniker SM, Hoppe RT
• Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
  Blood 2021 Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, Shustov AR, Horwitz SM, Hitz F, Cabrera ME, Dlouhy I, Vassallo J, Pileri SA, Inghirami G, Montoto S, Vitolo U, Radford J, Vose JM, …
• Pulmonary Manifestations of GATA2 Deficiency.
  Chest 2021 Marciano BE, Olivier KN, Folio LR, Zerbe CS, Hsu AP, Freeman AF, Filie AC, Spinner MA, Sanchez LA, Lovell JP, Parta M, Cuellar-Rodriguez JM, Hickstein DD, Holland SM
• CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
  Archives of pathology & laboratory medicine 2021 Menke JR, Spinner MA, Natkunam Y, Warnke RA, Advani RH, Gratzinger DA
• Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
  Blood advances 2021 Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, …
• Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
  Leukemia 2021 Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G,…
• T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.
  Blood advances 2020 Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, Yeung J, Spinner MA, Lunning M, Inghirami G, Moskowitz A, Galasso N, Ganesan N, van der Weyden C, Ruan J, Prince HM, Trotman J, Advani…
• Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
  The oncologist 2020 Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta …
• Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms.
  Blood advances 2020 Spinner MA, Aleshin A, Santaguida MT, Schaffert SA, Zehnder JL, Patterson AS, Gekas C, Heiser D, Greenberg PL
• Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
  British journal of haematology 2020 Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, …
• Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
  The oncologist 2020 Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, …
• Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
  Blood advances 2019 Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng WK, Hoppe RT, Strober S, Lowsky R
• Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD
• Risk-adapted therapy for advanced-stage Hodgkin lymphoma.
  Hematology. American Society of Hematology. Education Program 2018 Spinner MA, Advani RH
• Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
  British journal of haematology 2018 Spinner MA, Varma G, Advani RH
• Novel Approaches in Waldenström Macroglobulinemia.
  Hematology/oncology clinics of North America 2018 Spinner MA, Varma G, Advani RH
• Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.
  Blood advances 2018 Spinner MA, Advani RH, Hoppe RT, Lowsky R, Muffly LS
• New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018 Spinner MA, Advani RH, Connors JM, Azzi J, Diefenbach C
• HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
  Blood advances 2017 Spinner MA, Fernández-Viña M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR
• GATA2 deficiency underlying severe blastomycosis and fatal herpes simplex virus-associated hemophagocytic lymphohistiocytosis.
  The Journal of allergy and clinical immunology 2015 Spinner MA, Ker JP, Stoudenmire CJ, Fadare O, Mace EM, Orange JS, Hsu AP, Holland SM
• GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.
  Blood 2013 Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, …
• What does the duty to warn require?
  The American journal of bioethics : AJOB 2013 Shah SK, Hull SC, Spinner MA, Berkman BE, Sanchez LA, Abdul-Karim R, Hsu AP, Claypool R, Holland SM
• Duodenal histoplasmosis presenting with upper gastrointestinal bleeding in an AIDS patient.
  Case reports in gastrointestinal medicine 2012 Spinner MA, Paulin HN, Wester CW